Hua MedicineHUMDF 46 Receivables Turnover is 3.59 as of Dec. 2025. GuruFocus rates HUMDF with a GF Score™ of 46/100 and a GF Value™ of $1.16 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 950 Drug Manufacturers companies, Hua Medicine ranks better than 78% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Hua Medicine's Revenue for the
six
months ended in Dec. 2025 was $39.12 Mil. Hua Medicine's average Accounts Receivable for the
six
months ended in Dec. 2025 was $10.89 Mil.
Hence, Hua Medicine's Receivables Turnover for the
six
months ended in Dec. 2025 was 3.59.
Hua Medicine (OTCPK:HUMDF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Hua Medicine Receivables Turnover Related Terms
Hua Medicine Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Hua Medicine's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUMDF vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Hua Medicine's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a Receivables Turnover of 3.59 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hua Medicine and its competitors. According to the industry distribution chart, Hua Medicine ranks #209 out of 950 companies in the Drug Manufacturers industry, placing it in the top 22%.
Is Hua Medicine's Receivables Turnover too high?
Hua Medicine's current Receivables Turnover is 3.59. The Drug Manufacturers industry median Receivables Turnover is 5.07. Hua Medicine's value of 3.59 is 29.2% below this industry median. Based on the distribution chart, Hua Medicine ranks #209 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hua Medicine has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #209 out of 950 companies for Receivables Turnover. This places Hua Medicine in the top 22% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Hua Medicine's value of 3.59 is 29.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current Receivables Turnover of 3.59 is 29.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current Receivables Turnover is 3.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.16, compared to a current price of $0.34 — trading 70.7% below its estimated fair value. The current Receivables Turnover is 3.59 and 29.2% below the Drug Manufacturers industry median of 5.07. Hua Medicine's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current Receivables Turnover is 3.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.34 is trading 70.7% below its estimated GF Value™ of $1.16.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
Receivables Turnover: 3.59
GF Value™: $1.16 vs. price of $0.34 (70.7% below fair value)
Industry Position: 29.2% below the Drug Manufacturers median (#209 of 950)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score
Get the complete analysis for HUMDF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
